Interaction Checker

Interaksi Masitentan

Masitentan (Opsumit) memiliki 117 interaksi terdokumentasi dalam label FDA dan lembar fakta yang kami indeks: 77 mayor, 0 moderat, 40 minor, dan 0 dengan label yang melaporkan tidak ada interaksi bermakna. Setiap entri di bawah ini mengutip kalimat yang mendasarinya. Halaman obat ini adalah titik awal, bukan putusan untuk situasi Anda.

Interaksi dari label

Interaksi mayor (77)

  • AmiodaronantiaritmiaMayor

    Strong CYP3A4 inhibitors (ketoconazole, ritonavir) increase exposure to macitentan: avoid co-administration with OPSUMIT ( 7.2 , 12.3 ) . (label Masitentan, Interaksi obat)

  • Aprepitantpenghambat CYP3A4Mayor

    Strong CYP3A4 inducers (rifampin) reduce exposure to macitentan: avoid co-administration with OPSUMIT ( 7.1 , 12.3 ). (label Masitentan, Interaksi obat)

  • Armodafinilstimulan SSPMayor

    Strong CYP3A4 inducers (rifampin) reduce exposure to macitentan: avoid co-administration with OPSUMIT ( 7.1 , 12.3 ). (label Masitentan, Interaksi obat)

  • AtazanavirantiretroviralMayor

    Strong CYP3A4 inhibitors (ketoconazole, ritonavir) increase exposure to macitentan: avoid co-administration with OPSUMIT ( 7.2 , 12.3 ) . (label Masitentan, Interaksi obat)

  • Bismut subsitrat, metronidazol, dan tetrasiklinantibiotikMayor

    Moderate dual CYP3A4 and CYP2C9 inhibitors (fluconazole, amiodarone) or use of combined CYP3A4 and CYP2C9 inhibitors may increase exposure to macitentan: avoid co-administration with OPSUMIT ( 7.3 , 12.3 ). (label Masitentan, Interaksi obat)

  • Bosentanpenginduksi CYP3A4Mayor

    Strong CYP3A4 inducers (rifampin) reduce exposure to macitentan: avoid co-administration with OPSUMIT ( 7.1 , 12.3 ). (label Masitentan, Interaksi obat)

  • DarunavirantiretroviralMayor

    Strong CYP3A4 inhibitors (ketoconazole, ritonavir) increase exposure to macitentan: avoid co-administration with OPSUMIT ( 7.2 , 12.3 ) . (label Masitentan, Interaksi obat)

  • Darunavir dan kobisistatantiretroviralMayor

    Strong CYP3A4 inhibitors (ketoconazole, ritonavir) increase exposure to macitentan: avoid co-administration with OPSUMIT ( 7.2 , 12.3 ) . (label Masitentan, Interaksi obat)

  • Deferasirokssuplemen zat besiMayor

    Strong CYP3A4 inducers (rifampin) reduce exposure to macitentan: avoid co-administration with OPSUMIT ( 7.1 , 12.3 ). (label Masitentan, Interaksi obat)

  • DeksametasonkortikosteroidMayor

    Strong CYP3A4 inducers (rifampin) reduce exposure to macitentan: avoid co-administration with OPSUMIT ( 7.1 , 12.3 ). (label Masitentan, Interaksi obat)

  • Diltiazempenghambat kanal kalsiumMayor

    Strong CYP3A4 inhibitors (ketoconazole, ritonavir) increase exposure to macitentan: avoid co-administration with OPSUMIT ( 7.2 , 12.3 ) . (label Masitentan, Interaksi obat)

  • Disulfirampenghambat CYP2C9Mayor

    Moderate dual CYP3A4 and CYP2C9 inhibitors (fluconazole, amiodarone) or use of combined CYP3A4 and CYP2C9 inhibitors may increase exposure to macitentan: avoid co-administration with OPSUMIT ( 7.3 , 12.3 ). (label Masitentan, Interaksi obat)

  • DronedaronantiaritmiaMayor

    Strong CYP3A4 inhibitors (ketoconazole, ritonavir) increase exposure to macitentan: avoid co-administration with OPSUMIT ( 7.2 , 12.3 ) . (label Masitentan, Interaksi obat)

  • EfavirenzantiretroviralMayor

    Strong CYP3A4 inducers (rifampin) reduce exposure to macitentan: avoid co-administration with OPSUMIT ( 7.1 , 12.3 ). (label Masitentan, Interaksi obat)

  • Efavirenz, lamivudin, dan tenofovirantiretroviralMayor

    Strong CYP3A4 inducers (rifampin) reduce exposure to macitentan: avoid co-administration with OPSUMIT ( 7.1 , 12.3 ). (label Masitentan, Interaksi obat)

  • Elvitegravir, kobisistat, emtrisitabin, dan tenofovirantiretroviralMayor

    Strong CYP3A4 inhibitors (ketoconazole, ritonavir) increase exposure to macitentan: avoid co-administration with OPSUMIT ( 7.2 , 12.3 ) . (label Masitentan, Interaksi obat)

  • Eritromisinantibiotik makrolidaMayor

    Strong CYP3A4 inhibitors (ketoconazole, ritonavir) increase exposure to macitentan: avoid co-administration with OPSUMIT ( 7.2 , 12.3 ) . (label Masitentan, Interaksi obat)

  • EslikarbazepinantikonvulsanMayor

    Strong CYP3A4 inducers (rifampin) reduce exposure to macitentan: avoid co-administration with OPSUMIT ( 7.1 , 12.3 ). (label Masitentan, Interaksi obat)

  • EtravirinantiretroviralMayor

    Strong CYP3A4 inducers (rifampin) reduce exposure to macitentan: avoid co-administration with OPSUMIT ( 7.1 , 12.3 ). (label Masitentan, Interaksi obat)

  • EverolimusimunosupresanMayor

    Strong CYP3A4 inhibitors (ketoconazole, ritonavir) increase exposure to macitentan: avoid co-administration with OPSUMIT ( 7.2 , 12.3 ) . (label Masitentan, Interaksi obat)

  • FenitoinantikonvulsanMayor

    Strong CYP3A4 inducers (rifampin) reduce exposure to macitentan: avoid co-administration with OPSUMIT ( 7.1 , 12.3 ). (label Masitentan, Interaksi obat)

  • FenobarbitalbarbituratMayor

    Strong CYP3A4 inducers (rifampin) reduce exposure to macitentan: avoid co-administration with OPSUMIT ( 7.1 , 12.3 ). (label Masitentan, Interaksi obat)

  • Fentermin dan topiramatstimulan SSPMayor

    Strong CYP3A4 inducers (rifampin) reduce exposure to macitentan: avoid co-administration with OPSUMIT ( 7.1 , 12.3 ). (label Masitentan, Interaksi obat)

  • Flukonazolantijamur azolMayor

    Strong CYP3A4 inhibitors (ketoconazole, ritonavir) increase exposure to macitentan: avoid co-administration with OPSUMIT ( 7.2 , 12.3 ) . (label Masitentan, Interaksi obat)

  • FluorourasilantimetabolitMayor

    Moderate dual CYP3A4 and CYP2C9 inhibitors (fluconazole, amiodarone) or use of combined CYP3A4 and CYP2C9 inhibitors may increase exposure to macitentan: avoid co-administration with OPSUMIT ( 7.3 , 12.3 ). (label Masitentan, Interaksi obat)

  • FluvastatinstatinMayor

    Moderate dual CYP3A4 and CYP2C9 inhibitors (fluconazole, amiodarone) or use of combined CYP3A4 and CYP2C9 inhibitors may increase exposure to macitentan: avoid co-administration with OPSUMIT ( 7.3 , 12.3 ). (label Masitentan, Interaksi obat)

  • FosamprenavirantiretroviralMayor

    Strong CYP3A4 inhibitors (ketoconazole, ritonavir) increase exposure to macitentan: avoid co-administration with OPSUMIT ( 7.2 , 12.3 ) . (label Masitentan, Interaksi obat)

  • Fosaprepitantpenghambat CYP3A4Mayor

    Strong CYP3A4 inhibitors (ketoconazole, ritonavir) increase exposure to macitentan: avoid co-administration with OPSUMIT ( 7.2 , 12.3 ) . (label Masitentan, Interaksi obat)

  • FosfenitoinantikonvulsanMayor

    Strong CYP3A4 inducers (rifampin) reduce exposure to macitentan: avoid co-administration with OPSUMIT ( 7.1 , 12.3 ). (label Masitentan, Interaksi obat)

  • GriseofulvinantijamurMayor

    Strong CYP3A4 inducers (rifampin) reduce exposure to macitentan: avoid co-administration with OPSUMIT ( 7.1 , 12.3 ). (label Masitentan, Interaksi obat)

  • Imatinibpenghambat CYP3A4Mayor

    Strong CYP3A4 inhibitors (ketoconazole, ritonavir) increase exposure to macitentan: avoid co-administration with OPSUMIT ( 7.2 , 12.3 ) . (label Masitentan, Interaksi obat)

  • IsoniazidantibiotikMayor

    Strong CYP3A4 inhibitors (ketoconazole, ritonavir) increase exposure to macitentan: avoid co-administration with OPSUMIT ( 7.2 , 12.3 ) . (label Masitentan, Interaksi obat)

  • Itrakonazolantijamur azolMayor

    Strong CYP3A4 inhibitors (ketoconazole, ritonavir) increase exposure to macitentan: avoid co-administration with OPSUMIT ( 7.2 , 12.3 ) . (label Masitentan, Interaksi obat)

  • Ivakaftorpenghambat CYP3A4Mayor

    Strong CYP3A4 inhibitors (ketoconazole, ritonavir) increase exposure to macitentan: avoid co-administration with OPSUMIT ( 7.2 , 12.3 ) . (label Masitentan, Interaksi obat)

  • Kanabidiol (obat resep)antikonvulsanMayor

    Moderate dual CYP3A4 and CYP2C9 inhibitors (fluconazole, amiodarone) or use of combined CYP3A4 and CYP2C9 inhibitors may increase exposure to macitentan: avoid co-administration with OPSUMIT ( 7.3 , 12.3 ). (label Masitentan, Interaksi obat)

  • KapesitabinantimetabolitMayor

    Moderate dual CYP3A4 and CYP2C9 inhibitors (fluconazole, amiodarone) or use of combined CYP3A4 and CYP2C9 inhibitors may increase exposure to macitentan: avoid co-administration with OPSUMIT ( 7.3 , 12.3 ). (label Masitentan, Interaksi obat)

  • KarbamazepinantikonvulsanMayor

    Strong CYP3A4 inducers (rifampin) reduce exposure to macitentan: avoid co-administration with OPSUMIT ( 7.1 , 12.3 ). (label Masitentan, Interaksi obat)

  • Ketokonazolantijamur azolMayor

    Strong CYP3A4 inhibitors (ketoconazole, ritonavir) increase exposure to macitentan: avoid co-administration with OPSUMIT ( 7.2 , 12.3 ) . (label Masitentan, Interaksi obat)

  • Klaritromisinantibiotik makrolidaMayor

    Strong CYP3A4 inhibitors (ketoconazole, ritonavir) increase exposure to macitentan: avoid co-administration with OPSUMIT ( 7.2 , 12.3 ) . (label Masitentan, Interaksi obat)

  • KlobazambenzodiazepinMayor

    Strong CYP3A4 inducers (rifampin) reduce exposure to macitentan: avoid co-administration with OPSUMIT ( 7.1 , 12.3 ). (label Masitentan, Interaksi obat)

  • LenakapavirantiretroviralMayor

    Strong CYP3A4 inhibitors (ketoconazole, ritonavir) increase exposure to macitentan: avoid co-administration with OPSUMIT ( 7.2 , 12.3 ) . (label Masitentan, Interaksi obat)

  • Lopinavir dan ritonavirantiretroviralMayor

    Strong CYP3A4 inducers (rifampin) reduce exposure to macitentan: avoid co-administration with OPSUMIT ( 7.1 , 12.3 ). (label Masitentan, Interaksi obat)

  • Lorlatinibpenginduksi CYP3A4Mayor

    Strong CYP3A4 inducers (rifampin) reduce exposure to macitentan: avoid co-administration with OPSUMIT ( 7.1 , 12.3 ). (label Masitentan, Interaksi obat)

  • MetronidazolantibiotikMayor

    Moderate dual CYP3A4 and CYP2C9 inhibitors (fluconazole, amiodarone) or use of combined CYP3A4 and CYP2C9 inhibitors may increase exposure to macitentan: avoid co-administration with OPSUMIT ( 7.3 , 12.3 ). (label Masitentan, Interaksi obat)

  • Mifepristonpenghambat CYP3A4Mayor

    Strong CYP3A4 inhibitors (ketoconazole, ritonavir) increase exposure to macitentan: avoid co-administration with OPSUMIT ( 7.2 , 12.3 ) . (label Masitentan, Interaksi obat)

  • Mikonazolantijamur azolMayor

    Moderate dual CYP3A4 and CYP2C9 inhibitors (fluconazole, amiodarone) or use of combined CYP3A4 and CYP2C9 inhibitors may increase exposure to macitentan: avoid co-administration with OPSUMIT ( 7.3 , 12.3 ). (label Masitentan, Interaksi obat)

  • Mirabegronagonis beta-adrenergikMayor

    Strong CYP3A4 inhibitors (ketoconazole, ritonavir) increase exposure to macitentan: avoid co-administration with OPSUMIT ( 7.2 , 12.3 ) . (label Masitentan, Interaksi obat)

  • Mitapivatpenginduksi CYP3A4Mayor

    Strong CYP3A4 inducers (rifampin) reduce exposure to macitentan: avoid co-administration with OPSUMIT ( 7.1 , 12.3 ). (label Masitentan, Interaksi obat)

  • Mitotanpenginduksi CYP3A4Mayor

    Strong CYP3A4 inducers (rifampin) reduce exposure to macitentan: avoid co-administration with OPSUMIT ( 7.1 , 12.3 ). (label Masitentan, Interaksi obat)

  • Modafinilstimulan SSPMayor

    Strong CYP3A4 inducers (rifampin) reduce exposure to macitentan: avoid co-administration with OPSUMIT ( 7.1 , 12.3 ). (label Masitentan, Interaksi obat)

  • Nafsilinantibiotik penisilinMayor

    Strong CYP3A4 inducers (rifampin) reduce exposure to macitentan: avoid co-administration with OPSUMIT ( 7.1 , 12.3 ). (label Masitentan, Interaksi obat)

  • NefazodonantidepresanMayor

    Strong CYP3A4 inhibitors (ketoconazole, ritonavir) increase exposure to macitentan: avoid co-administration with OPSUMIT ( 7.2 , 12.3 ) . (label Masitentan, Interaksi obat)

  • NevirapinantiretroviralMayor

    Strong CYP3A4 inducers (rifampin) reduce exposure to macitentan: avoid co-administration with OPSUMIT ( 7.1 , 12.3 ). (label Masitentan, Interaksi obat)

  • Nirmatrelvir dan ritonavirantivirusMayor

    Strong CYP3A4 inhibitors (ketoconazole, ritonavir) increase exposure to macitentan: avoid co-administration with OPSUMIT ( 7.2 , 12.3 ) . (label Masitentan, Interaksi obat)

  • Nitisinonpenghambat CYP2C9Mayor

    Moderate dual CYP3A4 and CYP2C9 inhibitors (fluconazole, amiodarone) or use of combined CYP3A4 and CYP2C9 inhibitors may increase exposure to macitentan: avoid co-administration with OPSUMIT ( 7.3 , 12.3 ). (label Masitentan, Interaksi obat)

  • OkskarbazepinantikonvulsanMayor

    Strong CYP3A4 inducers (rifampin) reduce exposure to macitentan: avoid co-administration with OPSUMIT ( 7.1 , 12.3 ). (label Masitentan, Interaksi obat)

  • Palbosiklibpenghambat CYP3A4Mayor

    Strong CYP3A4 inhibitors (ketoconazole, ritonavir) increase exposure to macitentan: avoid co-administration with OPSUMIT ( 7.2 , 12.3 ) . (label Masitentan, Interaksi obat)

  • PerampanelantikonvulsanMayor

    Strong CYP3A4 inhibitors (ketoconazole, ritonavir) increase exposure to macitentan: avoid co-administration with OPSUMIT ( 7.2 , 12.3 ) . (label Masitentan, Interaksi obat)

  • Posakonazolantijamur azolMayor

    Strong CYP3A4 inhibitors (ketoconazole, ritonavir) increase exposure to macitentan: avoid co-administration with OPSUMIT ( 7.2 , 12.3 ) . (label Masitentan, Interaksi obat)

  • PrimidonantikonvulsanMayor

    Strong CYP3A4 inducers (rifampin) reduce exposure to macitentan: avoid co-administration with OPSUMIT ( 7.1 , 12.3 ). (label Masitentan, Interaksi obat)

  • Ranolazinobat yang memperpanjang interval QTMayor

    Strong CYP3A4 inhibitors (ketoconazole, ritonavir) increase exposure to macitentan: avoid co-administration with OPSUMIT ( 7.2 , 12.3 ) . (label Masitentan, Interaksi obat)

  • RifabutinantibiotikMayor

    Strong CYP3A4 inducers (rifampin) reduce exposure to macitentan: avoid co-administration with OPSUMIT ( 7.1 , 12.3 ). (label Masitentan, Interaksi obat)

  • RifampisinantibiotikMayor

    Strong CYP3A4 inducers (rifampin) reduce exposure to macitentan: avoid co-administration with OPSUMIT ( 7.1 , 12.3 ). (label Masitentan, Interaksi obat)

  • RifapentinantibiotikMayor

    Strong CYP3A4 inducers (rifampin) reduce exposure to macitentan: avoid co-administration with OPSUMIT ( 7.1 , 12.3 ). (label Masitentan, Interaksi obat)

  • RitonavirantiretroviralMayor

    Strong CYP3A4 inducers (rifampin) reduce exposure to macitentan: avoid co-administration with OPSUMIT ( 7.1 , 12.3 ). (label Masitentan, Interaksi obat)

  • SenobamatantikonvulsanMayor

    Strong CYP3A4 inducers (rifampin) reduce exposure to macitentan: avoid co-administration with OPSUMIT ( 7.1 , 12.3 ). (label Masitentan, Interaksi obat)

  • SiklosporinimunosupresanMayor

    Strong CYP3A4 inhibitors (ketoconazole, ritonavir) increase exposure to macitentan: avoid co-administration with OPSUMIT ( 7.2 , 12.3 ) . (label Masitentan, Interaksi obat)

  • Simetidinpenghambat H2Mayor

    Strong CYP3A4 inhibitors (ketoconazole, ritonavir) increase exposure to macitentan: avoid co-administration with OPSUMIT ( 7.2 , 12.3 ) . (label Masitentan, Interaksi obat)

  • Sulfametoksazol dan trimetoprim (kotrimoksazol)sulfonamidaMayor

    Moderate dual CYP3A4 and CYP2C9 inhibitors (fluconazole, amiodarone) or use of combined CYP3A4 and CYP2C9 inhibitors may increase exposure to macitentan: avoid co-administration with OPSUMIT ( 7.3 , 12.3 ). (label Masitentan, Interaksi obat)

  • Suvoreksantsedatif-hipnotikMayor

    Strong CYP3A4 inhibitors (ketoconazole, ritonavir) increase exposure to macitentan: avoid co-administration with OPSUMIT ( 7.2 , 12.3 ) . (label Masitentan, Interaksi obat)

  • Suzetriginpenginduksi CYP3A4Mayor

    Strong CYP3A4 inducers (rifampin) reduce exposure to macitentan: avoid co-administration with OPSUMIT ( 7.1 , 12.3 ). (label Masitentan, Interaksi obat)

  • TikagrelorantiplateletMayor

    Strong CYP3A4 inhibitors (ketoconazole, ritonavir) increase exposure to macitentan: avoid co-administration with OPSUMIT ( 7.2 , 12.3 ) . (label Masitentan, Interaksi obat)

  • TopiramatantikonvulsanMayor

    Strong CYP3A4 inducers (rifampin) reduce exposure to macitentan: avoid co-administration with OPSUMIT ( 7.1 , 12.3 ). (label Masitentan, Interaksi obat)

  • TrimetoprimantibiotikMayor

    Moderate dual CYP3A4 and CYP2C9 inhibitors (fluconazole, amiodarone) or use of combined CYP3A4 and CYP2C9 inhibitors may increase exposure to macitentan: avoid co-administration with OPSUMIT ( 7.3 , 12.3 ). (label Masitentan, Interaksi obat)

  • Verapamilpenghambat kanal kalsiumMayor

    Strong CYP3A4 inhibitors (ketoconazole, ritonavir) increase exposure to macitentan: avoid co-administration with OPSUMIT ( 7.2 , 12.3 ) . (label Masitentan, Interaksi obat)

  • Vorikonazolantijamur azolMayor

    Strong CYP3A4 inhibitors (ketoconazole, ritonavir) increase exposure to macitentan: avoid co-administration with OPSUMIT ( 7.2 , 12.3 ) . (label Masitentan, Interaksi obat)

  • Zafirlukastantagonis reseptor leukotrienMayor

    Moderate dual CYP3A4 and CYP2C9 inhibitors (fluconazole, amiodarone) or use of combined CYP3A4 and CYP2C9 inhibitors may increase exposure to macitentan: avoid co-administration with OPSUMIT ( 7.3 , 12.3 ). (label Masitentan, Interaksi obat)

Penyebutan minor (40)

  • Amiloriddiuretik hemat kaliumMinor

    Postmarketing cases of edema and fluid retention occurring within weeks of starting OPSUMIT, some requiring intervention with a diuretic or hospitalization for decompensated heart failure, have been reported [see Adverse Reactions (6.2) ] . (label Masitentan, Peringatan dan perhatian)

  • Asam etakrinatdiuretik loopMinor

    Postmarketing cases of edema and fluid retention occurring within weeks of starting OPSUMIT, some requiring intervention with a diuretic or hospitalization for decompensated heart failure, have been reported [see Adverse Reactions (6.2) ] . (label Masitentan, Peringatan dan perhatian)

  • Asetazolamidpenghambat karbonat anhidraseMinor

    Postmarketing cases of edema and fluid retention occurring within weeks of starting OPSUMIT, some requiring intervention with a diuretic or hospitalization for decompensated heart failure, have been reported [see Adverse Reactions (6.2) ] . (label Masitentan, Peringatan dan perhatian)

  • Atenolol dan klortalidonpenyekat betaMinor

    Postmarketing cases of edema and fluid retention occurring within weeks of starting OPSUMIT, some requiring intervention with a diuretic or hospitalization for decompensated heart failure, have been reported [see Adverse Reactions (6.2) ] . (label Masitentan, Peringatan dan perhatian)

  • Benazepril dan hidroklorotiazidpenghambat ACEMinor

    Postmarketing cases of edema and fluid retention occurring within weeks of starting OPSUMIT, some requiring intervention with a diuretic or hospitalization for decompensated heart failure, have been reported [see Adverse Reactions (6.2) ] . (label Masitentan, Peringatan dan perhatian)

  • Bisoprolol dan hidroklorotiazidpenyekat betaMinor

    Postmarketing cases of edema and fluid retention occurring within weeks of starting OPSUMIT, some requiring intervention with a diuretic or hospitalization for decompensated heart failure, have been reported [see Adverse Reactions (6.2) ] . (label Masitentan, Peringatan dan perhatian)

  • Bumetaniddiuretik loopMinor

    Postmarketing cases of edema and fluid retention occurring within weeks of starting OPSUMIT, some requiring intervention with a diuretic or hospitalization for decompensated heart failure, have been reported [see Adverse Reactions (6.2) ] . (label Masitentan, Peringatan dan perhatian)

  • Desogestrel dan etinilestradiolkontrasepsi oralMinor

    Advise patients who can become pregnant to use effective contraceptive methods prior to initiation of treatment, during treatment, and for one month after discontinuation of treatment with OPSUMIT. (label Masitentan, Peringatan dan perhatian)

  • Drospirenon dan etinilestradiolkontrasepsi oralMinor

    Advise patients who can become pregnant to use effective contraceptive methods prior to initiation of treatment, during treatment, and for one month after discontinuation of treatment with OPSUMIT. (label Masitentan, Peringatan dan perhatian)

  • Enalapril dan hidroklorotiazidpenghambat ACEMinor

    Postmarketing cases of edema and fluid retention occurring within weeks of starting OPSUMIT, some requiring intervention with a diuretic or hospitalization for decompensated heart failure, have been reported [see Adverse Reactions (6.2) ] . (label Masitentan, Peringatan dan perhatian)

  • Eplerenonantagonis aldosteronMinor

    Postmarketing cases of edema and fluid retention occurring within weeks of starting OPSUMIT, some requiring intervention with a diuretic or hospitalization for decompensated heart failure, have been reported [see Adverse Reactions (6.2) ] . (label Masitentan, Peringatan dan perhatian)

  • Estradiol dan dienogestkontrasepsi oralMinor

    Advise patients who can become pregnant to use effective contraceptive methods prior to initiation of treatment, during treatment, and for one month after discontinuation of treatment with OPSUMIT. (label Masitentan, Peringatan dan perhatian)

  • Etinodiol diasetat dan etinilestradiolkontrasepsi oralMinor

    Advise patients who can become pregnant to use effective contraceptive methods prior to initiation of treatment, during treatment, and for one month after discontinuation of treatment with OPSUMIT. (label Masitentan, Peringatan dan perhatian)

  • Fosinopril dan hidroklorotiazidpenghambat ACEMinor

    Postmarketing cases of edema and fluid retention occurring within weeks of starting OPSUMIT, some requiring intervention with a diuretic or hospitalization for decompensated heart failure, have been reported [see Adverse Reactions (6.2) ] . (label Masitentan, Peringatan dan perhatian)

  • Furosemiddiuretik loopMinor

    Postmarketing cases of edema and fluid retention occurring within weeks of starting OPSUMIT, some requiring intervention with a diuretic or hospitalization for decompensated heart failure, have been reported [see Adverse Reactions (6.2) ] . (label Masitentan, Peringatan dan perhatian)

  • Hidroklorotiaziddiuretik tiazidMinor

    Postmarketing cases of edema and fluid retention occurring within weeks of starting OPSUMIT, some requiring intervention with a diuretic or hospitalization for decompensated heart failure, have been reported [see Adverse Reactions (6.2) ] . (label Masitentan, Peringatan dan perhatian)

  • Indapamiddiuretik tiazidMinor

    Postmarketing cases of edema and fluid retention occurring within weeks of starting OPSUMIT, some requiring intervention with a diuretic or hospitalization for decompensated heart failure, have been reported [see Adverse Reactions (6.2) ] . (label Masitentan, Peringatan dan perhatian)

  • Irbesartan dan hidroklorotiazidpenghambat reseptor angiotensin II (ARB)Minor

    Postmarketing cases of edema and fluid retention occurring within weeks of starting OPSUMIT, some requiring intervention with a diuretic or hospitalization for decompensated heart failure, have been reported [see Adverse Reactions (6.2) ] . (label Masitentan, Peringatan dan perhatian)

  • Kandesartan dan hidroklorotiazidpenghambat reseptor angiotensin II (ARB)Minor

    Postmarketing cases of edema and fluid retention occurring within weeks of starting OPSUMIT, some requiring intervention with a diuretic or hospitalization for decompensated heart failure, have been reported [see Adverse Reactions (6.2) ] . (label Masitentan, Peringatan dan perhatian)

  • Klorotiaziddiuretik tiazidMinor

    Postmarketing cases of edema and fluid retention occurring within weeks of starting OPSUMIT, some requiring intervention with a diuretic or hospitalization for decompensated heart failure, have been reported [see Adverse Reactions (6.2) ] . (label Masitentan, Peringatan dan perhatian)

  • Klortalidondiuretik tiazidMinor

    Postmarketing cases of edema and fluid retention occurring within weeks of starting OPSUMIT, some requiring intervention with a diuretic or hospitalization for decompensated heart failure, have been reported [see Adverse Reactions (6.2) ] . (label Masitentan, Peringatan dan perhatian)

  • Kuinapril dan hidroklorotiazidpenghambat ACEMinor

    Postmarketing cases of edema and fluid retention occurring within weeks of starting OPSUMIT, some requiring intervention with a diuretic or hospitalization for decompensated heart failure, have been reported [see Adverse Reactions (6.2) ] . (label Masitentan, Peringatan dan perhatian)

  • Levonorgestrel dan etinilestradiolkontrasepsi oralMinor

    Advise patients who can become pregnant to use effective contraceptive methods prior to initiation of treatment, during treatment, and for one month after discontinuation of treatment with OPSUMIT. (label Masitentan, Peringatan dan perhatian)

  • Lisinopril dan hidroklorotiazidpenghambat ACEMinor

    Postmarketing cases of edema and fluid retention occurring within weeks of starting OPSUMIT, some requiring intervention with a diuretic or hospitalization for decompensated heart failure, have been reported [see Adverse Reactions (6.2) ] . (label Masitentan, Peringatan dan perhatian)

  • Losartan dan hidroklorotiazidpenghambat reseptor angiotensin II (ARB)Minor

    Postmarketing cases of edema and fluid retention occurring within weeks of starting OPSUMIT, some requiring intervention with a diuretic or hospitalization for decompensated heart failure, have been reported [see Adverse Reactions (6.2) ] . (label Masitentan, Peringatan dan perhatian)

  • Metolazondiuretik tiazidMinor

    Postmarketing cases of edema and fluid retention occurring within weeks of starting OPSUMIT, some requiring intervention with a diuretic or hospitalization for decompensated heart failure, have been reported [see Adverse Reactions (6.2) ] . (label Masitentan, Peringatan dan perhatian)

  • Metoprolol dan hidroklorotiazidpenyekat betaMinor

    Postmarketing cases of edema and fluid retention occurring within weeks of starting OPSUMIT, some requiring intervention with a diuretic or hospitalization for decompensated heart failure, have been reported [see Adverse Reactions (6.2) ] . (label Masitentan, Peringatan dan perhatian)

  • NoretisteronprogestinMinor

    Advise patients who can become pregnant to use effective contraceptive methods prior to initiation of treatment, during treatment, and for one month after discontinuation of treatment with OPSUMIT. (label Masitentan, Peringatan dan perhatian)

  • Noretisteron dan etinilestradiolkontrasepsi oralMinor

    Advise patients who can become pregnant to use effective contraceptive methods prior to initiation of treatment, during treatment, and for one month after discontinuation of treatment with OPSUMIT. (label Masitentan, Peringatan dan perhatian)

  • Norgestimat dan etinilestradiolkontrasepsi oralMinor

    Advise patients who can become pregnant to use effective contraceptive methods prior to initiation of treatment, during treatment, and for one month after discontinuation of treatment with OPSUMIT. (label Masitentan, Peringatan dan perhatian)

  • Norgestrel dan etinilestradiolkontrasepsi oralMinor

    Advise patients who can become pregnant to use effective contraceptive methods prior to initiation of treatment, during treatment, and for one month after discontinuation of treatment with OPSUMIT. (label Masitentan, Peringatan dan perhatian)

  • Olmesartan dan hidroklorotiazidpenghambat reseptor angiotensin II (ARB)Minor

    Postmarketing cases of edema and fluid retention occurring within weeks of starting OPSUMIT, some requiring intervention with a diuretic or hospitalization for decompensated heart failure, have been reported [see Adverse Reactions (6.2) ] . (label Masitentan, Peringatan dan perhatian)

  • Olmesartan, amlodipin, dan hidroklorotiazidpenghambat reseptor angiotensin II (ARB)Minor

    Postmarketing cases of edema and fluid retention occurring within weeks of starting OPSUMIT, some requiring intervention with a diuretic or hospitalization for decompensated heart failure, have been reported [see Adverse Reactions (6.2) ] . (label Masitentan, Peringatan dan perhatian)

  • Spironolaktonantagonis aldosteronMinor

    Postmarketing cases of edema and fluid retention occurring within weeks of starting OPSUMIT, some requiring intervention with a diuretic or hospitalization for decompensated heart failure, have been reported [see Adverse Reactions (6.2) ] . (label Masitentan, Peringatan dan perhatian)

  • Spironolakton dan hidroklorotiazidantagonis aldosteronMinor

    Postmarketing cases of edema and fluid retention occurring within weeks of starting OPSUMIT, some requiring intervention with a diuretic or hospitalization for decompensated heart failure, have been reported [see Adverse Reactions (6.2) ] . (label Masitentan, Peringatan dan perhatian)

  • Telmisartan dan hidroklorotiazidpenghambat reseptor angiotensin II (ARB)Minor

    Postmarketing cases of edema and fluid retention occurring within weeks of starting OPSUMIT, some requiring intervention with a diuretic or hospitalization for decompensated heart failure, have been reported [see Adverse Reactions (6.2) ] . (label Masitentan, Peringatan dan perhatian)

  • Torasemiddiuretik loopMinor

    Postmarketing cases of edema and fluid retention occurring within weeks of starting OPSUMIT, some requiring intervention with a diuretic or hospitalization for decompensated heart failure, have been reported [see Adverse Reactions (6.2) ] . (label Masitentan, Peringatan dan perhatian)

  • Triamterendiuretik hemat kaliumMinor

    Postmarketing cases of edema and fluid retention occurring within weeks of starting OPSUMIT, some requiring intervention with a diuretic or hospitalization for decompensated heart failure, have been reported [see Adverse Reactions (6.2) ] . (label Masitentan, Peringatan dan perhatian)

  • Triamteren dan hidroklorotiaziddiuretik hemat kaliumMinor

    Postmarketing cases of edema and fluid retention occurring within weeks of starting OPSUMIT, some requiring intervention with a diuretic or hospitalization for decompensated heart failure, have been reported [see Adverse Reactions (6.2) ] . (label Masitentan, Peringatan dan perhatian)

  • Valsartan dan hidroklorotiazidpenghambat reseptor angiotensin II (ARB)Minor

    Postmarketing cases of edema and fluid retention occurring within weeks of starting OPSUMIT, some requiring intervention with a diuretic or hospitalization for decompensated heart failure, have been reported [see Adverse Reactions (6.2) ] . (label Masitentan, Peringatan dan perhatian)

Periksa Masitentan terhadap semua yang Anda gunakan. Tambahkan seluruh daftar Anda; setiap pasangan diperiksa sekaligus.

Buka di pemeriksa

Bukan nasihat medis. Tingkat keparahan mencerminkan kata-kata dalam label, bukan keadaan Anda. Tanda “mayor” bisa merupakan hal yang rutin di bawah pengawasan, dan tanda “minor” bisa menjadi penting pada dosis tinggi. Tanyakan kepada apoteker.